Definiens, Munich, Germany, has signed a partnership agreement with MolecularMD Corp, Portland, Ore, to combine MolecularMD’s expertise in specialty diagnostic assays with Definiens’ quantitative tissue read-outs. MolecularMD is a molecular diagnostics company that develops custom companion diagnostic products and supports clinical trial services for targeted cancer therapies.
“Definiens’ technology already empowers smarter tissue-based diagnostics,” says Merrilyn Datta, chief commercial officer at Definiens. “This agreement brings together MolecularMD’s proven track record in clinical assay development and companion diagnostics with Definiens’ unparalleled image analysis platform to provide the confidence of an integrated solution in stratifying patients.”
The new partnership will provide custom solutions that meet data and regulatory requirements for both biopharmaceutical clients and academic medical center oncology programs, including advanced solutions with assays, image analysis, and data mining, combined with scientific, regulatory, and pathology support.
“MolecularMD is uniquely suited to assist biopharmaceutical clients and academic medical centers with our clinical trial and regulatory expertise,” says Dan Snyder, president and chief executive at MolecularMD. “I’m thrilled that Definiens and MolecularMD have joined forces to provide these unique advantages, accelerating pipeline decisions and dramatically improving patient stratification from the preclinical phase.”